Tag: Stem Cell Therapy
A systematic survey of the scientific literature shows that stem cell therapy can have a statistically significant impact on animal models of spinal cord injury, and points the way for future studies.
Spinal cord injuries are mostly caused by trauma, often incurred in road traffic or sporting incidents, often with devastating and irreversible consequences, and unfortunately having a relatively high prevalence (250,000 patients in the USA; 80% of cases are male). High-profile campaigners like the late actor Christopher Reeve, himself a victim of sports-related spinal cord injury, have placed high hopes in stem cell transplantation. But how likely is it to work?
Allogeneic and autogolous stem cell therapy combined with physical rehabilitation: A case report on...
This is a research paper written by Rebecca Johnston, Daniel Leonard’s sister. She recently graduated from a Physical Therapy degree program, and wrote her Capstone paper about Daniel’s stem cell therapy treatment in Panama.
Daniel is presented anonymously in the paper, but Rebecca and Daniel have given their permission for this paper to be shared. Daniel’s ASIA scores (pre and post treatment) are in the appendix of this paper.
European researchers have made significant progress in the attempt to treat spinal cord injuries using stem cell therapy. Although there have been several attempt to cure spinal cord injury patients, the results were not so encouraging.
Now, however, the project “From stem cell technology to functional restoration after spinal cord injury ‘(Rescue) has promising results so far.
Thirty Percent of Patients Show Improved Functioning after Stem Cell Therapy
Philadelphia, Pa. (May 17, 2012) – One of the first long-term studies of stem cell treatment for spinal cord injury shows significant functional and other improvements in three out of ten patients, reports a study in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Recent news that Geron has abruptly pulled out of the embryonic stem cell (ESC) business, after having just begun the only human clinical trials with ESC’s, has been met with deserved rejoicing by the pro-life community. While it certainly is a blow to the ESC movement, it doesn’t necessarily signal the impending implosion of the ESC industry.
Not by a long shot.
After years of controversy, a therapy based on human embryonic stem cells is finally being tested in humans. The treatment holds out hope to paralyzed people, but at how great a risk?
Hans Keirstead wakes up every morning at his home near Los Angeles and checks CNN. He’s looking for news about the first-ever human test of embryonic stem cells, launched in October by the biotechnology firm Geron. Mostly, he’s looking for bad news. “If someone dies, or is in pain, then it’s over,” he says, pushing a hand through his tawny hair. Keirstead, dressed in a loose linen shirt and wearing a thumb ring, is a biologist at the University of California, Irvine, who has variously been called the “rock star,” “miracle worker,” and “Pied Piper” of stem-cell science. Today he has a corner office in a new $67 million research center paid for in part by California voters, whom he helped persuade to vote for a $3 billion stem-cell spending plan in 2004 with a video of partially paralyzed rats walking again after stem-cell transplants performed in his laboratory.
Dr. Donald Leslie, medical director at the Shepherd Center in Atlanta, has high hopes.
“We want to cure paralysis,” he said. “We want to stop spinal cord injury. How incredible would that be?”
Leslie’s mission has begun with T.J. Atchinson, the first step in research that he believes could lead to many steps for those who were told they would never walk again. Atchinson, 21, was the first human with a spinal cord injury to undergo embryonic stem cell therapy.
The athletic college student’s life took a hard turn in September when he was home from the University of Alabama visiting his family in Chatom and lost control of his car. Even before he was cut loose from the vehicle, he knew something was wrong.
In the six months since scientists announced they had infused a drug made from human embryonic stem cells into a partially paralyzed patient’s spine, the identity of the recipient has been shrouded in secrecy.
Recently, rumors began circulating in Internet chat rooms that details about the closely guarded experiment were finally about to be revealed.
The $1 million price tag for a trial injecting nose cells into spinal-injury patients would be better spent helping people live with their disabilities, some experts say.
However, those involved with the trial say the New Zealand study will have international significance and funding everyday needs is like pouring money into a “great bottomless pit”.
The Ministry of Health multi-region ethics committee gave consent this week for an experimental trial which will see cells from people’s noses injected into the site of their spinal injuries.
Twelve paraplegics, half of whom will have the operation, will be accepted for the trial. The remaining six in the control group will get intensive rehabilitation.
Case Western Reserve University School of Medicine and Athersys, Inc. announced a joint scientific study on spinal cord injury will be published today in the January issue of the Journal of Neuroscience. The study, by leading researchers from the Department of Neurosciences at the School of Medicine and scientists at Athersys, presents data supporting the potential therapeutic benefit of Athersys’ MultiStem program for spinal cord injury.